Eli Lilly and Company Sees Buyouts As Way To Repair Depleted Pipeline

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eli Lilly & Co., is looking to a bevy of new medicines now in development to repair a pipeline depleted by the company’s recent loss of key exclusive patents. But long R&D and regulatory lead times before a drug hits the market has placed near-term revenue forecasts for the drugmaker under a cloud. Indianapolis-based Lilly may need acquisitions to boost its prospects.

Help employers find you! Check out all the jobs and post your resume.

Back to news